click below
click below
Normal Size Small Size show me how
ABIM Nep GN & Renal
ABIM Nep GNs & Renal Diseases
Question | Answer |
---|---|
Alpha-1 antitrypsin is assoc with which ANCA? | anti-PR3 but not anti-MPO |
Describe IgG4-related disease. | Marked plasma cell infiltrate (tubulointerstitial nephritis) + autoimmune pancreatitis, but all organs affected. IgG4 deposited in the tubules. ++activate complement. May see eosinophilia and low+ANA , MGN, obstruction . pulm and renal masses. |
What disease presents with picture of low complements, AIN, renal/lung masses, low grade fever? | IgG4-related systemic disease. |
What disease presents with picture of pulmonary, eye, skin, and renal involvement, along with renal biopsy findings of a cellular infiltrate and granuloma? | sarcoidosis |
What disease presents with picture of dry eye, sicca syndrome, and interstitial nephritis (without granuloma) +/- systemic inflammation? | autoimmune dz of Sjögren’s syndrome. Usu no glomerular dz. |
What disease presents with picture of uveitis + interstitial nephritis (sometimes granulomas), fanconi syn? | TINU. idiopathic IAN + ant uveitis usu in adolescent girls. |
What disease presents with picture of | |
von Hippel-Lindau syndrome abnormalities include? | cysts in the kidneys, pancreas, and genital tract. increased risk of developing clear cell renal cell carcinoma and pancreatic neuroendocrine tumor & pheochromocytoma |
What disease presents with skin papule, cystic kidney disease, possible mental retardation? | Tuberous Sclerosis |
When do you start IS for IgAN? | IgA nephropathy "with persistent proteinuria > 1 g daily, despite 3-6 months of med rx(ACE-I or ARBs & BP control), and GFR > 50 mL/min/1.73 m2, receive a 6-month course of corticosteroid therapy.” |
Tumors assoc w tuberous sclerosis? | angiomyolipomas. AD inheritance Major bleeding rx’d w/ nephron-sparing surgery |
How can mTORs help in tuberous sclerosis? | mTOR pathway, may be effective in markedly reducing the volume of target angiomyolipomas. |
Thrombotic thrombocytopenic purpura is diagnosed with what lab test? | ADAMTS13 activity LESS THAN 5% |
Albumin < ___ is the most significant independent predictor of venous thrombotic risk in NS? | 2.8 g/dL. Clin J Am Soc Nephrol. 2012;7:43-51 |
Rx IgAN? | 6-mo prednisone for persistent proteinuria >1 g/24 hr after a 3-6 therapeutic trial of RAAS ing & adequate BP control. Nephrol Dial Transplant. 2009; 24:3694-3701 |
Poor prognostic indicators for IgAN? | HTN, impaired GFR at presentation, and proteinuria. J Am Soc Nephrol. 2012;23:1753-1760 |
Abnormalities of alternative pathway cause what renal issues? | C3GN and DDD. Caused by factor H defect/deficiency or antibodies against alt complement pathway (aka C3 nephritic factor). assoc w low C3 and nl C4. |
Rx C3GN? | Eculizumab. Two recent reports utilizing Ecu for DDD or C3 GN were assoc w stabilization of GFR and improved renal path or less proteinuria in some but not all patients. J Am Soc Nephrol. 2012;23:1229-1237 |
Nephrotic syndrome in inflammatory bowel disease caused by? | Secondary (AA) amyloidosis. Often assoc w/ orthostasis suggesting autonomic neuropathy, hematuria (fragile bladder mucosa), |
Renal conditions w Crohn’s? | Mesalamine-induced AIN, calcium oxalate stones. |
Most common histologic entity associated with adult-onset nephrotic syndrome in Caucasians? | Membranous nephropathy |
Biopsy findings of membranous GN? | LM thickened capillary walls; PAS shows spikes; IF + IgG + complement. EM subepithelial deposits give “spike” appearance. |
target for MGN rx? | partial remission (<3.5 g/d & 50% reduction from peak proteinuria). Partial remission is assoc w both significant slowing CKD progression & doubling of kidney survival at 10 years |
Risk of progression from membranous GN | complete remissions in proteinuria occur in 20% to 30%. Low risk for progression if nl GFR & prot <4g. High-risk if proteinuria ≥8 g/d over 3 to 6 mo and/or declining CrCl during this observation period. medium risk if in between. |
Rx for primary MGN | steroids + cytotoxic (cyclophosphamide, chlorambucil, MMF) for med risk. BUT high risk pt start w/ cyclosporine. Resistant cases-ACTHAR, rituximab, |
Rx FSGS | prednisone 1 mg/kg max 60 g/d x 3-6 mos; CsA 3-5 mg/kg/d divided BID x 6-12 mos; tacrolimus 0.2-0.3 mg/kg/d divided BID x 6-12 mos; MMF 25-35 mg/kg/d divided BID (max 2g/d) WITH dex. [tac or CsA slow taper] |
Distinguish thin BM dz vs Alport. | Thin BM dz has GBM that is thin throughout. Alports has some thick/thin areas. |
Thin Basement membrane clinical features | min proteinuria, hematuria, nl GFR, benign course. May be carrier state of Alport. |
Alport clinical features | persistent hematuria, proteinuria 1-2g/d, renal failure progressive, deafness, lenticonus, Leiomyomitosis, cognitive impairment, retinopathy. X-linked most common. Carriers look like thin BM. |
Sub epithelial deposits on EM are classic of _____ GN. | membranous nephropathy, + PLA2R. Decline of anti-PLA2R titer precedes clinical response. |
_______ is the first podocytic antigen responsible for human membranous nephropathy (MN) in adults. | Thrombospondin type-1 domain-containing 7A (THSD7A). Neutral endopeptidase (NEP) in neonates & cationic bovine serum albumin (cBSA in children. |
cANCA pattern associated with ____ | PR3 (think c3po). Has higher rate of relapse |
pANCA pattern associated with ____ | MPO (think c3po) |
Microscopic Polyangiitis (MPA) | Pauciimune necrotizing vasculitis of small/medium arteries. Associated with pulmonary disease |
Hemolytic uremic syndrome without diarrhea is known as _______ | atypical HUS. Could be from infections or complement deficiency (acquired/inherited). |
T/F alternate pathway is constantly activated at low levels . | TRUE. It is usually turned off, but failure to down regulate (by Factor H 1, etc) results in unchecked complement activation. |
C3GN | previously called MPGN. no IgG deposition or staining but ++C3 stain. Caused by alternative pathway dysregulation from abnormal proteins or antibodies. |
C3nephritic factor present + DDD treatment is ______ | plasma exchange or infusion, Rituximab |
CFH mutation present in DDD treatment is ______ | plasma infusion |
T/F FSGS tip lesion has worst prognosis. | False since has best prognosis |
T/F FSGS collapsing lesion has worst prognosis | TRUE. Maybe idiopathic or secondary to viral infections, medications |
T/F FSGS NOS is rare | FALSE. It’s most common. |
T/F FSGS cellular variant is rare | TRUE; it is the least common |
Viruses associated w FSGS | HIV, parvo B19, HCV, CMV, EBV |
Drugs assoc w FSGS | pamidronate, heroin, interferon, lithium, calcineurin inh |
APOL1 associated with? | collapsing FSGS, HIVAN, sickle cell, SLE, focal global sclerosis (HTN). 2 risk variants assoc w 20% chance of developing renal dz. |
Genetic testing for FSGS | usu not done, but NPHS2pR229Q is a permissive mutation that requires 2cnd mutation (compound heterozygotes) to cause FSGS. esp common in Western Europe. |
Nail patella syndrome | AD loss of fcn mutation of LMX1B, assos w symmetric nail, skeletal, ocular and kidney disease. Biopsy + “whorling” pattern. |
When is genetic testing for FSGS undertaken? | children w congenital NS, children w SRNS, familial FSGS, (sopradic FSGS consider R229Q NPHS2 variant) |
AL-Type Amyloidosis histology | Renal, pul, GI & cardiac involvement most common. definitive dx congo red stain apple birefringence; amorphous eosinophilic nodular infiltrate in glom. IF + smudgy lambda>kappa. EM random oriented fibrils. |
Immunotactoid acute tubulopathy looks like? | glomerular deposits, Large organized fibril in GBM. IF + either kappa or lamb not both; EM Tubular deposits > 30 nm |
LCDD acute tubulopathy looks like? | fanconi + AKI + LC crystals (light blue on H&E). EM: LC crystals needle shaped, rectangular, rod-like and electron dense. |
T/F Free light chains maybe elevated with low GFR. | true |
The presence of free light chains indicates a biopsy when ____. | kappa/lambda ratio is skewed (ie normal is 0.26 - 1.6). Especially with tubulopathy and AKI. |
Rituximab in ANCA-Associated Vasculitis (RAVE) trial showed | ritux + steroids had similar results to cyclophosphamide+steroids for induction of remission and may be superior in relapsing disease. Alveolar hemorrhage pts had same outcomes but relapsers fared better in ritux arm. Similar SAE noted. |
LCCD histology | nodular glomerulsclerosis; IF makes dx staining for kappa>lambda; EM finely granular amorphous deposits |
HIV assoc kidney disease? | HIVAN, MCD, postinfectious GN, amyloidosis, and IgAN. Coinfection with hepatitis B and C common—> MGN + MPGN |
myeloma kidney presents with _______ | prox RTA (tubulopathy), acidic urine, usu kappa chains. UA trace pro, + glu, bland sediment. 24 hr urine ++ protein. Labs show nl glucose, low phos |
AKI + back pain make you think of? | multiple myeloma |
ESRD + back pain make you think of? | paraspinal abscess from bacteremia |
What agent is contraindicated to treat/prevent TLS in G6PD deficient pts? | Rasburicase. |
T/F Rasburicase.and allopurinol are equally effective to treat TLS. | TRUE |
Role of allopurinol in TLS? | safe drug assuming good kidney function. Lowers further uric acid production but does NOT correct pre-existing hyperuricemia. |
T/F alkalinizing urine is recommended for TLS. | NO. IV saline is best. watch if patient has AKI or vol overload. Increasing the urine pH decreases UA precipitation that enhances Ca-Ph precipitation. |
Histologic features of FSGS? | LM shows segmental sclerosis, focal. IF: NO immune complex deposition… but may rarely see IgM in scarred areas. EM: extensive foot process effacement (>80%) |
Amyloid path diagnosis? | AKI, CKD, + lambda light chains, +SPEP/EPEP, proteinuria, hyperglycemia, NODULES, linear staining on IF for mesangial collagen. congo red +apple-green birefringence |
Renal microaneurysms are found in? | Polyarteritis nodosa |
Polyarteritis nodosa affects which vessels? | small and medium sized arteries, especially Reno and visceral, nerves and coronaries… Causes aneurysms that look like tiny bead |
Classic EM finding of Alports? | is variable thickening, thinning, basket weaving, and lamellation of GBM |
Classic EM finding of thin basement membrane disease? | GBM Thickness measuring < 200nm |
Dense deposit disease is best treated with _____. | eculizumab. |
The best treatment for C3GN is —-. | Rituximab + plasma exchange (eculizumab) has been shown to be useful in Rx of DDD, aHUS). |
RITUXIMAB has been shown to be useful in RX of___. | ANCA vasculitis (induction or relapse per RAVE TRIAL), GPA(Wegener’s), HCV cryoglobulinemia or C3GN, TTP. [Rituximab has not been useful in DDD which is rx'd w ecu or plasma.] |
Renal effects of antibodies against epidermal growth factor (cetuximab, panitumumab, matuzumab) | renal magnesium wasting in the distal tubule. Hypomagnesemia was associated with hypokalemia and hypocalcemia. |
Syndromes that cause hypoMg | Barrters, Gitelmans |